EUVIMEDEUVIMED entdecken
LeitlinieOpen Access · CC BY-NC-ND 4.0

Japanese Society of Medical Oncology clinical guidelines: Molecular testing for colorectal cancer treatment, 5th edition

Hideaki Bando iD, Kyoko Yamaguchi, Seiichiro Mitani, Kentaro Sawada, Saori Mishima iD, Keigo Komine, Yoshinaga Okugawa, Waki Hosoda iD, Hiromichi Ebi iD

Cancer Science · 2024-03 · 115 (3) · 1014-1021

DOI: 10.1111/cas.16039 ↗

Kurz gefasst

Leitlinie in der Zeitschrift Cancer Science, online erschienen am 23.01.2024. Verfasst von Hideaki Bando und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology and Gastrointestinal Oncology, National Cancer Center Hospital East, Chiba, Japan. Hauptthemen laut MEDLINE: Circulating Tumor DNA, Colorectal Neoplasms. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 21 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Japanese Society of Medical Oncology.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Molecular testing to determine optimal therapies is essential for managing patients with colorectal cancer (CRC). In October 2022, the Japanese Society of Medical Oncology published the 5th edition of the Molecular Testing Guideline for Colorectal Cancer Treatment. In this guideline, in patients with unresectable CRC, RAS / BRAF V600E mutational and mismatch repair tests are strongly recommended prior to first‐line chemotherapy to select optimal first‐ and second‐line therapies. In addition, HER2 testing is strongly recommended because the pertuzumab plus trastuzumab combination is insured after fluoropyrimidine, oxaliplatin, and irinotecan in Japan. Circulating tumor DNA (ctDNA)‐based RAS testing is also strongly recommended to assess the indications for the readministration of anti‐EGFR antibodies. Both tissue‐ and ctDNA‐based comprehensive genomic profiling tests are strongly recommended to assess the indications for targeted molecular drugs, although they are currently insured in patients with disease progression after receiving standard chemotherapy (or in whom disease progression is expected in the near future). Mutational and mismatch repair testing is strongly recommended for patients with resectable CRC, and RAS/BRAF V600E mutation testing is recommended to estimate the risk of recurrence. Mutational and mismatch repair and BRAF testing are also strongly recommended for screening for Lynch syndrome. Circulating tumor DNA‐based minimal residual disease (MRD) testing is strongly recommended for estimating the risk of recurrence based on clinical evidence, although MRD testing was not approved in Japan at the time of the publication of this guideline.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Circulating Tumor DNAColorectal NeoplasmsHumansJapanProto-Oncogene Proteins B-rafMutationMolecular Diagnostic TechniquesDisease ProgressionMedical Oncology

Stichwörter der Autor:innen

circulating tumor DNAcolorectal cancercomprehensive genomic profilingguidelinemicrosatellite instability

Substanzen

Circulating Tumor DNAProto-Oncogene Proteins B-raf

Autor:innen und Institutionen

  • Department of Gastroenterology and Gastrointestinal Oncology, National Cancer Center Hospital East, Chiba, Japan.
  • Department of Hematology, Oncology, and Cardiovascular Medicine, Kyushu University Hospital, Fukuoka, Japan.
  • Department of Medical Oncology, Kindai University Faculty of Medicine, Osaka-Sayama, Japan.
  • Department of Clinical Oncology, Kushiro Rosai Hospital, Kushiro, Japan.
  • Department of Medical Oncology, Tohoku University Hospital, Sendai, Japan.
  • Department of Genomic Medicine, Mie University Faculty of Medicine, Tsu, Japan.

ORCID-Profile: Hideaki Bando, Saori Mishima, Waki Hosoda, Hiromichi Ebi

Förderung

  • Japanese Society of Medical Oncology

Zitieren

APA

Bando, H., Yamaguchi, K., Mitani, S., Sawada, K., Mishima, S., Komine, K., Okugawa, Y., Hosoda, W., & Ebi, H. (2024). Japanese Society of Medical Oncology clinical guidelines: Molecular testing for colorectal cancer treatment, 5th edition. Cancer Science, 115(3), 1014-1021. https://doi.org/10.1111/cas.16039

Vancouver

Bando H, Yamaguchi K, Mitani S, Sawada K, Mishima S, Komine K, et al. Japanese Society of Medical Oncology clinical guidelines: Molecular testing for colorectal cancer treatment, 5th edition. Cancer Science. 2024;115(3):1014-1021. doi:10.1111/cas.16039

BibTeX
@article{Bando2024,
  author = {Bando, Hideaki and Yamaguchi, Kyoko and Mitani, Seiichiro and Sawada, Kentaro and Mishima, Saori and Komine, Keigo and Okugawa, Yoshinaga and Hosoda, Waki and Ebi, Hiromichi},
  title = {Japanese Society of Medical Oncology clinical guidelines: Molecular testing for colorectal cancer treatment, 5th edition},
  journal = {Cancer Science},
  year = {2024},
  volume = {115},
  number = {3},
  pages = {1014--1021},
  doi = {10.1111/cas.16039}
}
Kostenlos starten →